Clinical Trial

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Study acronym: KYLIN-3
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Efficacy and Safety of Vebreltinib in Combination With PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFR Mutations, MET Amplification and/or Overexpression, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Following EGFR-TKI Treatment Failure
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-06; most recent amendment 2025-05-20.
Trial Details
NCT Number NCT06970782
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions Non-Small-Cell Lung Cancer
Enrollment 278 participants
Start Date 2025-05-15
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-21